Invention Grant
- Patent Title: Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha
-
Application No.: US18239892Application Date: 2023-08-30
-
Publication No.: US12103907B2Publication Date: 2024-10-01
- Inventor: Joel Worley Beatty , Samuel Lawrie Drew , Matthew Epplin , Jeremy Thomas Andre Fournier , Balint Gal , Tezcan Guney , Karl T. Haelsig , Clayton Hardman , Steven Donald Jacob , Jenna Leigh Jeffrey , Jaroslaw Kalisiak , Kenneth Victor Lawson , Manmohan Reddy Leleti , Erick Allen Lindsey , Artur Karenovich Mailyan , Debashis Mandal , Guillaume Mata , Hyunyoung Moon , Jay Patrick Powers , Brandon Reid Rosen , Yongli Su , Anh Thu Tran , Zhang Wang , Xuelei Yan , Kai Yu
- Applicant: ARCUS BIOSCIENCES, INC.
- Applicant Address: US CA Hayward
- Assignee: Arcus Biosciences, Inc.
- Current Assignee: Arcus Biosciences, Inc.
- Current Assignee Address: US CA Hayward
- Agency: Foley & Lardner LLP
- Agent Brittany J. Perla
- The original application number of the division: US17205273 2021.03.18
- Main IPC: C07C317/32
- IPC: C07C317/32 ; A61K31/10 ; A61K31/277 ; A61K31/343 ; A61K31/353 ; A61K31/365 ; A61K31/381 ; A61K31/404 ; A61K31/415 ; A61K31/416 ; A61K31/4174 ; A61K31/4192 ; A61K31/4196 ; A61K31/421 ; A61K31/423 ; A61K31/426 ; A61K31/428 ; A61K31/437 ; A61K31/44 ; A61K31/4412 ; A61K31/47 ; A61K31/4709 ; A61K31/472 ; A61K31/4965 ; A61K31/50 ; A61K31/5025 ; A61K31/505 ; A61K31/519 ; A61K31/538 ; A61K39/395 ; A61K45/06 ; C07C255/53 ; C07C317/22 ; C07C317/36 ; C07D209/34 ; C07D211/86 ; C07D213/57 ; C07D213/71 ; C07D213/73 ; C07D213/74 ; C07D213/84 ; C07D215/48 ; C07D217/04 ; C07D231/12 ; C07D231/56 ; C07D233/64 ; C07D237/20 ; C07D239/42 ; C07D241/12 ; C07D249/06 ; C07D249/08 ; C07D263/32 ; C07D263/57 ; C07D265/36 ; C07D277/30 ; C07D277/56 ; C07D277/64 ; C07D307/83 ; C07D311/22 ; C07D333/64 ; C07D401/04 ; C07D401/10 ; C07D409/10 ; C07D413/10 ; C07D471/04 ; C07D487/04
Abstract:
Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.
Public/Granted literature
- US20240254079A1 TETRALIN AND TETRAHYDROQUINOLINE COMPOUNDS AS INHIBITORS OF HIF-2ALPHA Public/Granted day:2024-08-01
Information query
